The companies said they plan to develop multiple mRNA vaccine candidates and hope to develop a single vaccine that will be effective against multiple variants. The vaccine, if approved, may be used to protect people who haven’t been vaccinated or as a booster for people who have been vaccinated.
They said their goal is to get a vaccine candidate approved next year.
GlaxoSmithKline has agreed to support CureVac’s manufacturing of its current COVID-19 vaccine candidate, which is in late-stage clinical trials. GlaxoSmithKline said it will manufacture up to 100 million doses of the vaccine.
Read the full news release here.
More articles on pharmacy:
APhA urges HHS to allow retired pharmacists, pharmacy techs to give vaccines
US COVID-19 vaccinations exceed positive tests for virus, Bloomberg reports
FDA to streamline process to approve vaccines updated for protection against virus variants
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
